Over the next decade, GLP-1 RAs could reshape the trajectory of chronic disease in the U.S., potentially improving millions of lives and reducing downstream healthcare costs. However, the scale and equity of impact will hinge on pricing, policy decisions, and access strategies. For hospitals and healthcare providers, the shift may require rethinking care delivery models—from managing complex chronic patients to promoting upstream prevention.

Driving in South Florida has become for me a time when I am able to listen to various podcasts. While listening to podcasts talking about the Florida State Seminoles might rate very high, as I was recently driving to a meeting in Fort Lauderdale I listened to a podcast featuring Dr. Eric Topol.

For those of you who have not read or heard about Dr. Topol, he is a prominent American cardiologist, geneticist, and digital health advocate known for his visionary leadership in the convergence of medicine and technology. A professor of molecular medicine at Scripps Research and founder of the Scripps Research Translational Institute, Dr. Topol has been a pioneer in promoting precision medicine, artificial intelligence in healthcare, and the democratization of medical information.

“While the three researchers —Daniel Drucker, Joel Haebner and Jens Juul Holst —who discovered GLP-1 have been widely and appropriately recognized for this groundbreaking work, it was developed exclusively for the treatment of diabetes.” It has been an uphill battle (two decades) getting this drug recognized as a treatment for obesity. Now, the possibilities have opened up in terms of new uses for this family of drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).

Parkinson’s Disease?

In several, but small, randomized clinical trials using lixisentaide, a GLP-1 drug, participants who received the drug experience no change in their Movement Disorder Scale-Unified Parkinson’s Disease Rating Scale. In a couple of studies using exenatide, “There is a strong indication that GLP-1 receptor agonists may have a useful role in future treatment of Parkinson’s disease.” Of interest, lixisenatide and exenatide are much weaker GLP-1 drugs compared with semaglutide.

Obesity/Weight Loss?

In nine clinical trials of both injectable and oral administrations, average weight loss ranges from 15 to 25 pounds. Also noted are significant reductions in overall inflammation preceding weight loss.

Heart Failure?

“More than half of patients with heart failure have preserved pump function, as quantified by ejection fraction. Their heart failure symptoms and physical limitations are due to impaired filling and relaxation of the left ventricle.”

Neurological Disorders?

EVOKE and EVOKE+ Trials: These studies are investigating semaglutide’s potential in treating early-stage Alzheimer’s disease. Preliminary findings suggest that GLP-1 RAs may slow cognitive decline by addressing multiple pathological processes involved in Alzheimer’s.

The list seems endless. I haven’t mentioned used of semaglutide in treating addictive disorders or even sleep apnea. This is just one family of drugs that hold great promise. With the use of AI, what other advances will be seeing in the near future?